Public COA audit

Tirzepatide

Audited July 28, 2026

Evidence suggests fabrication

Multiple signals on this document conflict with known lab formats or verification patterns.

Legitimacy
25
Confidence
85%
Panels
4/7
Purity (printed)
99.9%

Document details

Fields extracted from the certificate — not order or payment data.

Batch / lot
TIR100-0616
Identity method
MALDI-MS
Sample date
2026-06-19
Issue date
2026-06-25

7-panel checklist

Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.

4 of 7 present · 4 passed · 0 failed · 0 reported · 3 missing

Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.

  • Identity

    Tested · passed · core

    Compound identity confirmed (e.g. HPLC, mass spec).

    Tirzepatide

  • Purity

    Tested · passed · core

    Reported purity percentage for the analyte.

    99.9%

  • Heavy metals

    Tested · passed

    Lead, arsenic, cadmium, mercury, or similar limits.

    <0.01 ppm

  • Microbial

    Not on this COA

    Bioburden / microbial limits testing.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Endotoxin

    Tested · passed · core

    LAL or chromogenic endotoxin assay.

    <0.05 EU/mL

  • Sterility

    Not on this COA

    Sterility testing where applicable.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Residual solvent / water

    Not on this COA

    Residual solvents or water content limits.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

How to read this

Had data · good

Panel present with a pass (or clear acceptance).

Had data · bad

Panel present with a fail — a concrete quality signal.

Had data · unclear

Value reported without an explicit pass/fail mark.

Missing

Not on this certificate. Lowers thoroughness; you decide if that panel matters for your use case. PeptIQ’s score still factors coverage.

Findings

Evidence-linked observations from this audit.

  • Future dates (2026)

    Sample received June 19, 2026 and COA issued June 25, 2026 - both dates are in the future, which is impossible for a legitimate document created in 2024 or earlier

  • Unverifiable lab entity

    Bioviridian does not appear to be a known, established analytical testing laboratory. The domain bioviridians.com and verification URL cannot be independently verified as belonging to a legitimate testing facility

  • Suspiciously high purity

    99.9% purity for a complex peptide like Tirzepatide (39 amino acids) is exceptionally high and unusual, particularly for a lyophilized powder from a research vendor

  • Generic template appearance

    Document uses a generic template design that could be easily replicated. Lacks unique security features, watermarks, or lab-specific formatting typical of established analytical labs

  • Product image inclusion

    The inclusion of a vendor product vial image (with Aminos Peptides branding) on an analytical COA is unusual - legitimate third-party labs typically do not include vendor marketing materials

  • Lot number present

    Batch/lot number TIR100-0616 is clearly stated

  • Multiple test panels

    Document shows identity, purity, endotoxin, and heavy metals testing with specific methods cited

PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.